Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lorusso

Showing results (231-240 of 280) with videos related to

Pageof 28
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid MalignanciesDejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Oncotarget|April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinomaPriscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomasMonica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Journal of Clinical Pharmacology|December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Biochemical Pharmacology|December 7, 2020
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cellsIsabel Alvarado-Cruz, Mariam Mahmoud, Mohammed Khan, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicineSara Nasser, Ahmet A Kurdolgu, Tyler Izatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2017
<sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast CancerHelen Lee, Anthony F Shields, Barry A Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Pageof 28

Showing results (231-240 of 280) with videos related to

Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid MalignanciesDejan Juric, Johann S de Bono, Patricia M LoRusso, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 2022
Correction: A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Oncotarget|April 19, 2017
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinomaPriscila H Goncalves, Lance K Heilbrun, Michael T Barrett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomasMonica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Journal of Clinical Pharmacology|December 3, 2014
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenibA Benjamin Suttle, Kenneth F Grossmann, Daniele Ouellet, et al.
Biochemical Pharmacology|December 7, 2020
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cellsIsabel Alvarado-Cruz, Mariam Mahmoud, Mohammed Khan, et al.
Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing|January 17, 2015
An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicineSara Nasser, Ahmet A Kurdolgu, Tyler Izatt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2016
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid TumorsJeffrey R Infante, Antoine Hollebecque, Sophie Postel-Vinay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2017
<sup>64</sup>Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast CancerHelen Lee, Anthony F Shields, Barry A Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumorsPatricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Pageof 28